<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">FMAR</journal-id><journal-title-group><journal-title>Forensic Medicine and Anatomy Research</journal-title></journal-title-group><issn pub-type="epub">2327-4115</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/fmar.2018.62003</article-id><article-id pub-id-type="publisher-id">FMAR-83958</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Light and Electron Microscopic Study of the Effect of Orlistat on the Liver of Adult Male Albino Rats and the Possible Protective Role of &lt;i&gt;β&lt;/i&gt;-Carotene
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sahar</surname><given-names>Youssef</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Anatomy Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt</addr-line></aff><author-notes><corresp id="cor1">* E-mail:</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>04</month><year>2018</year></pub-date><volume>06</volume><issue>02</issue><fpage>20</fpage><lpage>36</lpage><history><date date-type="received"><day>5,</day>	<month>March</month>	<year>2018</year></date><date date-type="rev-recd"><day>21,</day>	<month>April</month>	<year>2018</year>	</date><date date-type="accepted"><day>24,</day>	<month>April</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Orlistat is a safe and effective drug to treat obesity by acting as a pancreatic and gastric lipase inhibitor, resulting in reduction in fat absorption. There is also concern that it may be linked with an increased threat of serious hepatic incidents. The present work was carried out to study the effect of orlistat on the histological, immunohistochemical and electron microscopic structure of the liver in the adult male albino rats and the possible protective role of 
  &lt;i&gt;β&lt;/i&gt;-carotene administration. Forty adult albino rats were subjected to experiment for two weeks as follows: group 1 (control), group II, each animal received 0.52 mg/kg bw/day 
  &lt;i&gt;β&lt;/i&gt;-Carotene, group III, each animal received orlistat 32 mg/kg/day, and group IV received 
  &lt;i&gt;β&lt;/i&gt;-Carotene, 1hour before the administration of orlistat at same dose of group II &amp; III. The liver from each animal was dissected out and processed for histological, (light and electron microscopic study). The result of Hep-Par1 for immunohistochemistry was statistically analyzed. The results showed that orlistat treated group displayed variable disturbance of liver architecture, from dilatation, congested central and portal veins, branching of bile ductules, mononuclear cellular infiltration, areas of hemorrhages, cytoplasmic vacuolation and pyknotic nuclei. The most obvious changes were that degenerative changes in hepatocytes led to depletion of glycogen content of hepatocytes. Hep Par-1 revealed a wide area of negative immune expression around the central vein and in some hepatocytes. Other hepatocytes expressed weak reaction. Ultrastructure examination displayed hepatocytes with swollen mitochondria and others with an electron-dense matrix. The combined treatment of 
  &lt;i&gt;β&lt;/i&gt;-Carotene and orlistat led to a marked improvement in most of the previously mentioned changes. It was concluded that orlistat-induced hepatic toxicity. Thus, clinicians should cautiously monitor their patients for signs of hepatic dysfunction. Using an antioxidant such as 
  &lt;i&gt;β&lt;/i&gt;-Carotene decreased the toxicity of orlistat.
 
</p></abstract><kwd-group><kwd>Liver</kwd><kwd> Orlistat</kwd><kwd> Ultrastructure</kwd><kwd> &lt;i&gt;β&lt;/i&gt;-Carotene</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Obesity has been involved in many chronic conditions, comprising cardiovascular disease, diabetes mellitus, hypertension, obstructive sleep apnoea, hyperlipidaemia, fatty liver disease and malignancy [<xref ref-type="bibr" rid="scirp.83958-ref1">1</xref>]. Orlistat was official by the Food and Drug Administration (FDA) in 1998 for weight loss. Crucially, orlistat is the first gastrointestinal lipase inhibitor for the management of obesity [<xref ref-type="bibr" rid="scirp.83958-ref2">2</xref>]. Orlistat is a dominant inhibitor of gastrointestinal lipase. Following oral administration, orlistat is excreted nearly completely in the feces within three to five days, undergoes slight systemic absorption and displayed no accumulation [<xref ref-type="bibr" rid="scirp.83958-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.83958-ref4">4</xref>]. Orlistat deactivated gastrointestinal lipase, decreasing the absorption of dietary fat [<xref ref-type="bibr" rid="scirp.83958-ref5">5</xref>]. Significantly, orlistat diminished fat absorption by binding covalently to the serine residue of the active site of gastric and pancreatic lipases. It was suggested that orlistat administration with fat comprising foods partly prevented the hydrolysis of triglycerides, hence decreasing the consequent absorption of monoglycerides and free fatty acids [<xref ref-type="bibr" rid="scirp.83958-ref6">6</xref>]. The XENDOS study, which compared orlistat to placebo in over 3000 patients, showed statistically significant and sustained weight loss at the end of a 4-year study [<xref ref-type="bibr" rid="scirp.83958-ref7">7</xref>]. Orlistat, 120 mg in combination with diet has been shown to reduce liver fat in patients with type 2 diabetes [<xref ref-type="bibr" rid="scirp.83958-ref8">8</xref>] and reduce inflammation and fibrosis in non-alcoholic steatohepatitis [<xref ref-type="bibr" rid="scirp.83958-ref9">9</xref>]. Significantly, orlistat improved blood pressure, insulin resistance and serum lipid levels [<xref ref-type="bibr" rid="scirp.83958-ref10">10</xref>]. Moreover, orlistat has also been shown to decrease total cholesterol and low-density lipoprotein levels independent of weight loss [<xref ref-type="bibr" rid="scirp.83958-ref11">11</xref>]. Recent investigations recommended that orlistat was more effective in dropping weight and lipid profile than metformin [<xref ref-type="bibr" rid="scirp.83958-ref12">12</xref>]. However, the most commonly gastrointestinal adverse effects of orlistat include diarrhea, flatulence, bloating, abdominal pain and dyspepsia [<xref ref-type="bibr" rid="scirp.83958-ref10">10</xref>]. Orlistat is metabolized in the gastrointestinal tract and its direct damaging effect is publicized in intestinal villi of animal models [<xref ref-type="bibr" rid="scirp.83958-ref13">13</xref>]. Pancreatitis associated with the use of orlistat was also recorded by several investigators [<xref ref-type="bibr" rid="scirp.83958-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.83958-ref15">15</xref>]. The effect of orlistat on the liver is still a matter of controversy. Moreover, the mechanism of orlistat-induced hepatotoxicity remains indistinct.</p><p>The daily multivitamins with orlistat are co-prescribed to inhibit fat-soluble vitamin deficits [<xref ref-type="bibr" rid="scirp.83958-ref16">16</xref>]. At present, the hepatoprotective drugs are insufficient, even though the recently developed drugs have been used often have adverse effects. Therefore, a special interest has been directed to the use antioxidants in the treatment and may have an important role in maintaining health [<xref ref-type="bibr" rid="scirp.83958-ref17">17</xref>].</p><p>β-Carotene is considered a carotenoid which performed as a vitamin A precursor, and it is the most abundant form of vitamin A in fruits and vegetables [<xref ref-type="bibr" rid="scirp.83958-ref17">17</xref>]. It has antioxidant capability by scavenging free radicals and quenching singlet oxygen [<xref ref-type="bibr" rid="scirp.83958-ref18">18</xref>]. Animals are unable to synthesize carotenoids de novo, and they are dependent on the diet as a source of these compounds [<xref ref-type="bibr" rid="scirp.83958-ref19">19</xref>]. Van Poppel suggested that diet fruits and vegetables rich in β-Carotene or high blood levels of β-Carotene are linked with a reduced risk of cancer at lung and stomach [<xref ref-type="bibr" rid="scirp.83958-ref20">20</xref>]. Previous investigation demonstrated that β-carotene has not been revealed to precipitate vitamin A toxicity [<xref ref-type="bibr" rid="scirp.83958-ref21">21</xref>].</p><p>The Hepatocyte Paraffin antigen-1 (HepPar-1) is a mitochondrial urea cycle antigen. Several reports have been increasingly used Hep-Par1 as a positive biomarker for hepatic distinction [<xref ref-type="bibr" rid="scirp.83958-ref22">22</xref>].</p><p>Taken together, the incidence of obesity has been markedly increased worldwide, and many people are interested to decrease their weight by the administration of orlistat. The current work aimed to study the histological, immunohistochemical and electron microscopic changes that may occur in the liver of adult male albino rats after treatment with orlistat and to evaluate the possibility of protection of β-carotene.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Animals</title><p>This study was carried out on forty adult male albino rats. They were weighed between 150 - 200 g each. Rats were housed in separate well-ventilated cages, under standard conditions, with free access to standard diet and water ad libitum. Rats were kept at a controlled temperature of 25˚C &#177; 1˚C and under a 12 h. light: 12 h. dark schedule. Rats were left for two week before the start of experiments for acclimatization. Rats used in this study bought from the Central Animal House, Faculty of Medicine, Assiut University. All animal procedures were in agreement with the principles guidelines for the carefulness and use of experimental animals by the Committee for the Purpose of Supervision of Experiments on Animals. Furthermore, all animals processes were in accordance to the National Institute of Health (NIH) protocol and they agreed by the Institutional Ethics Committee of Assiut University.</p></sec><sec id="s2_2"><title>2.2. Drugs and Chemicals</title><p>Orlistat was purchased as a capsule with a trade name (REGIMAX) Produced by Global Napi Pharmaceuticals (GNP), Penta Pharma, Egypt.</p></sec><sec id="s2_3"><title>2.3. Experimental Design</title><p>The animals were divided into four equal groups (10 rats each). Rats were subjected to experiment for two weeks as follows:</p><p>1) Group I (Control group): Rats received 1 ml of fish oil, the vehicle for orlistat, orally by a gastric tube once daily.</p><p>2) Group II (β-carotene group): Rats received β-carotene supplementation at 0.52 mg/kg body weight (BW)/day [<xref ref-type="bibr" rid="scirp.83958-ref23">23</xref>].</p><p>3) Group III (Orlistat treated group): Rats received orlistat dissolved in fish oil orally by a gastric tube at a dose of 32 mg/kg/day [<xref ref-type="bibr" rid="scirp.83958-ref24">24</xref>]. The orlistat dose was calculated according to the interspecies dose conversion scheme by Paget and Branes [<xref ref-type="bibr" rid="scirp.83958-ref25">25</xref>].</p><p>4) Group IV (Orlistat &amp; β-carotene group): Rats received β-carotene supplementation at 0.52 mg/kg bw/day, one hour before the administration of orlistat dose of 32 mg/kg/day. Both orlistat and β-carotene were administered orally.</p></sec><sec id="s2_4"><title>2.4. Histological Study</title><p>The liver specimens was dissected out and divided into two halves by longitudinal section. One half was processed for light microscopic investigation, whereas the other was processed for electron microscopic investigation. The liver specimens were fixed in a 10% formalin solution and they were processed and embedded in paraffin wax by routine protocol. 3 - 4 μm thick sections were obtained and stained with Haematoxylin and Eosin to study the general structure [<xref ref-type="bibr" rid="scirp.83958-ref26">26</xref>]. Periodic acid Schiff's reaction (PAS) technique was used for the study of mucopolysaccharides and polysaccharides [<xref ref-type="bibr" rid="scirp.83958-ref27">27</xref>].</p></sec><sec id="s2_5"><title>2.5. Immunohistochemical Study</title><p>For the immunohistochemical study, 4 μm paraffin sections were mounted on charged slides coated on polylysine. The immunohistochemical stain were performed for localization of hepatocyte mitochondrial membrane antigen using hepatocyte paraffin-1 (Hep Par-1). The liver sections were deparaffinized in xylene, rehydrated in descending grades of alcohol. The antigen retrieval was carried out by treating the liver sections with 0.1 mol/L, citrate buffer at pH 6.0 for ten minutes in a microwave at 100˚C for twenty minutes, and subsequently left to cool at room temperature for another twenty minutes. To block the endogenous peroxidase, the slides were incubated in hydrogen peroxide, 3% for five minutes. Then, they were washed twice in PBS for five minutes each. Sections were incubated with the primary antibody, anti-HepPar-1 mouse monoclonal antibody (Lab vision, USA). The primary antibody was diluted at 1:100 overnight at room temperature [<xref ref-type="bibr" rid="scirp.83958-ref28">28</xref>]. After rinsing in PBS, the liver tissues were incubated with a biotin bound to secondary antibody (DAKO-EnVision Plus System-HRP). The peroxidase reaction was visualized using diaminobenzidine (DAB). The sections were counterstained with Mayer’s hematoxylin before examination under microscope followed by dehydration, clearing and then mounting. Normal liver tissues were used as the positive controls, however, the negative control liver slides were achieved by omitting the primary antibody and subsequently, no immunostaining was occurred. Finally, the Hep Par-1 positivity appeared as coarsely granular brown cytoplasmic staining. The investigation and photography were conducted at the Mycology and Biotechnology Unit, Al-Azhar University, Cairo, Egypt.</p></sec><sec id="s2_6"><title>2.6. Morphometric Study</title><p>Quantitative morphometric measurements were done by using the image analyser Leica Qwin standard, 500c, England. The image analyser was calibrated automatically to transform the measurement units, the pixels formed by the image analyser program into real micrometer units. Using the measuring field menu, the area % and standard measuring frame were chosen from the parameters. The area percentage for HepPar-1 immunoreaction in hepatocytes was measured using the objective lens of magnification 40, total magnification, &#215;400. Ten readings were achieved in each specimen and the mean values were done.</p></sec><sec id="s2_7"><title>2.7. Statistical Analysis</title><p>The data obtained were subjected to statistical analysis using SPSS statistical software (SPSS for Windows, version 13.0). Comparison between groups was made using ANOVA. All data were expressed as mean (&#177;) SD. The Results were considered significant when the P value less than 0.05 (P &lt; 0.05).</p></sec><sec id="s2_8"><title>2.8. Electron Microscopy Study</title><p>Liver Specimens for electron microscopy were immediately fixed in 2.5% gluteraldehyde for 24 hours. Then liver specimens were washed in 3 - 4 changes of cacodylate buffer (pH 7.2) for 20 minutes each. The postfixation was done in cold 1% osmium tetroxide for 2 hours and they were washed in four changes of cacodylate buffer for twenty minutes each. The specimens were dehydrated by using ascending grades of alcohol and clearing were carried out in propylene oxide. Embedding was carried out in Epon 812 using gelatin capsules. For polymerization, the embedded samples were kept in an incubator at 35˚C for one day, incubator at 45˚C for another day, and finally incubator at 60˚C for three days. The semi-thin sections of 1-μm thickness were cut and they stained with toluidine blue. Ultrathin sections (500 - 800) from selected areas of trimmed blocks were collected on copper grids. The ultrathin sections were then contrasted in uranyl acetate for ten minutes and in lead acetate for five minutes. Sections were examined by a transmission electron microscope and JEOL 100 CX, (Japan) and photographed at 80 kV at the Assiut University, Electron Microscopy Unit.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Histological Results</title><p>The liver sections stained with H&amp;E of the control group (group I) showed the normal histological architecture. The cells appeared as cords radiating from central veins. The hepatic cells appeared polygonal in shape with rounded vesicular nuclei and a granular acidophilic cytoplasm. The cords were separated from each other by blood sinusoids. The hepatic sinusoids appeared as narrow spaces between the hepatic plates which lined by flat endothelial cells (<xref ref-type="fig" rid="fig1">Figure 1</xref>(A)).</p><p>The liver sections stained with H&amp;E of the β-Carotene-treated group (group II) showed a normal hepatic structure. The hepatocytes were arranged in the form of plates radiating from the central vein (<xref ref-type="fig" rid="fig1">Figure 1</xref>(B)). The hepatocytes were polyhedral with acidophilic granular cytoplasm. They had large rounded central vesicular nuclei (<xref ref-type="fig" rid="fig1">Figure 1</xref>(B)).</p><p>The liver sections stained with H&amp;E of the orlistat treated group (group III) showed extensive mononuclear cellular infilteration. The cellular infilteration extend to portal tract (<xref ref-type="fig" rid="fig1">Figure 1</xref>(C)). The liver sections showed dilated and congested central veins (<xref ref-type="fig" rid="fig1">Figure 1</xref>(D)). The hepatocytes displayed loss of normal hepatic architecture with vacuolated cytoplasm (<xref ref-type="fig" rid="fig1">Figure 1</xref>(D)). The dilatation and congested portal veins was also detected. Proliferation of bile ducts, branching of bile ductules, and periportal mononuclear cellular infiltration were also observed. Some hepatocyte nuclei were shrunken and deeply stained (<xref ref-type="fig" rid="fig1">Figure 1</xref>(E)).</p><p>The liver sections stained with H&amp;E of the orlistat and β-Carotene -treated group displayed an apparent improvement in the hepatocytes compared with those treated with orlistat. The hepatocytes appeared normal but some cells still revealed vacuolated cytoplasm. The blood sinusoids were still dilated (<xref ref-type="fig" rid="fig1">Figure 1</xref>(F)). Binucleated hepatocytes were detected (<xref ref-type="fig" rid="fig1">Figure 1</xref>(F)).</p></sec><sec id="s3_2"><title>3.2. Histochemical Results</title><p>The control liver section stained with PAS revealed a substantial amount of polysaccharides granules in the ground cytoplasm of hepatocytes (<xref ref-type="fig" rid="fig2">Figure 2</xref>(A)).</p><p>The β-Carotene liver section stained with PAS showed normal glycogen distribution in the cytoplasm of hepatocytes (<xref ref-type="fig" rid="fig2">Figure 2</xref>(B)).</p><p>The orlistat liver section stained with PAS revealed areas with negative PAS reaction (<xref ref-type="fig" rid="fig2">Figure 2</xref>(C)). Reduction of polysaccharide content in many hepatocytes was observed, however, few hepatocytes still exhibited extensive amount of polysaccharides (<xref ref-type="fig" rid="fig2">Figure 2</xref>(C)).</p><p>The orlistat and β-Carotene liver section stained with PAS displayed heterogeneous intensity of PAS reaction. Some hepatocytes revealed a strong PAS reaction (<xref ref-type="fig" rid="fig2">Figure 2</xref>(D)). While other hepatocytes exhibited a moderate PAS reaction (<xref ref-type="fig" rid="fig2">Figure 2</xref>(D)).</p></sec><sec id="s3_3"><title>3.3. Immunohistochemical Results</title><p>Immunohistochemical results for Hep Par-1 in the control liver section showed strong positive Hep Par-1 immunoreaction in the form of coarsely scattered granules throughout the hepatocytes cytoplasm with narrow negative immunoreaction around the central vein (<xref ref-type="fig" rid="fig3">Figure 3</xref>(A)).</p><p>The β-Carotene liver section for Hep Par-1 displayed strong expression of Hep Par-1 in the form of granular cytoplasmic immunoreaction of hepatocytes with negative immunoreaction around in the portal tract (<xref ref-type="fig" rid="fig3">Figure 3</xref>(B)).</p><p>The orlistat liver section for Hep Par-1 revealed a wide area of negative immune expression around the central vein and in some hepatocyte was observed (<xref ref-type="fig" rid="fig3">Figure 3</xref>(C)). Other hepatocytes expressed weak reaction (<xref ref-type="fig" rid="fig3">Figure 3</xref>(C)).</p><p>The Orlistat and β-Carotene liver section for Hep-Par1 exhibited patchy positive immunoreactivity for Hep Par-1. Some hepatocytes revealed strong granular cytoplasmic expression (<xref ref-type="fig" rid="fig3">Figure 3</xref>(D)). Other hepatocytes expressed weak immune reaction for Hep Par1. In addition, moderate area of negative immune reaction around the central vein can be seen (<xref ref-type="fig" rid="fig3">Figure 3</xref>(D)).</p></sec><sec id="s3_4"><title>3.4. Electron Microscopy Results</title><p>The ultrastructure of the control group showed normal hepatic cell with rounded or oval euchromatic nucleus and prominent nucleolus. The well-developed nuclear membrane was detected. The cytoplasm was crowded with cell organelles, the most numerous, the mitochondria and the rough endoplasmic reticulum. The organelles were situated around the nucleus (<xref ref-type="fig" rid="fig4">Figure 4</xref>(A)).</p><p>The ultrastructure of β-Carotene group showed hepatocytes with euochromatic rounded nuclei. The cytoplasm contained many mitochondria and rough endoplasmic reticulum (<xref ref-type="fig" rid="fig4">Figure 4</xref>(B)).</p><p>The ultrastructure of orlistat group showed some of the hepatocytes appeared with small darkly stained nuclei (<xref ref-type="fig" rid="fig4">Figure 4</xref>(C), <xref ref-type="fig" rid="fig4">Figure 4</xref>(D) and <xref ref-type="fig" rid="fig5">Figure 5</xref>(C)). Crucially, the mitochondria were numerous, large or giant that they are clearly observed (<xref ref-type="fig" rid="fig5">Figure 5</xref>(A), <xref ref-type="fig" rid="fig5">Figure 5</xref>(B)). Obviously, some of them had electron-dense matrix as well as dense granules (<xref ref-type="fig" rid="fig5">Figure 5</xref>(A), <xref ref-type="fig" rid="fig5">Figure 5</xref>(B)). The cytoplasm showed dilated proliferated endoplasmic reticulum (<xref ref-type="fig" rid="fig4">Figure 4</xref>(C)), some vacuoles (<xref ref-type="fig" rid="fig4">Figure 4</xref>(C), <xref ref-type="fig" rid="fig4">Figure 4</xref>(D) and <xref ref-type="fig" rid="fig5">Figure 5</xref>(C)) and lipid droplets were also detected (<xref ref-type="fig" rid="fig4">Figure 4</xref>(C)).</p><p>The ultrastructure of Orlistat and β-Carotene group revealed most of the hepatocytes appeared more or less normal with rounded nucleus (<xref ref-type="fig" rid="fig5">Figure 5</xref>(D)). The numerous mitochondria and slightly dilated rough endoplasmic reticulum were detected (<xref ref-type="fig" rid="fig5">Figure 5</xref>(D)).</p></sec><sec id="s3_5"><title>3.5. Mean Area % of Hep-Par 1 Immunoreactivity</title><p>Morphometric analysis of β-Carotene group (Group II) showed that the mean area percentage of Hep-Par 1 revealed almost normal value which was statistically insignificant compared with group I (P &gt; 0.05). Expressively, marked decrease in the mean area percentage of Hep-Par 1in the group III of orlistat treated group (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref>) which was statistically significant compared with the mean value of the control group (Group I). Crucially, manifest increase in group IV which was statistically significant as compared with the orlistat group (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref>).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>In the present study, the administration of orlistat induced alterations in the light and electron microscopic structures of the rat liver. The light microscopic structure orlistat group displayed congested portal and central veins. Crucially, the divergent blood vessel dilatation could recommend metabolic disturbances in the liver, thus signifying a potential harm effect of orlistat on the liver. Significantly, an increase in mononuclear cellular infiltration was also detected in the periportal areas. This result has been described by some researchers [<xref ref-type="bibr" rid="scirp.83958-ref29">29</xref>]. The inflammatory cellular infiltration observed in the orlistat treated group were in</p><p>agreement with investigators who proposed that reactive oxygen species with lipid peroxidation products may cause mitochondrial dysfunction, which can lead to apoptosis and necrosis, activating a cascade leading to fibrosis and collagen deposition [<xref ref-type="bibr" rid="scirp.83958-ref30">30</xref>]. Previous investigators explained that the inflammatory mediators made in hepatocytes, such as TNF-α, are most expected to act in a paracrine manner to favor liver injury and hence mononuclear cellular infiltration [<xref ref-type="bibr" rid="scirp.83958-ref31">31</xref>].</p><p>In the current study, orlistat group showed liver damage in the form of hepatocellular necrosis as manifested by enlargement of the hepatocytes with cytoplasmic vacuolations and pyknotic nuclei. The present results are in agreement with previous reports that suggested that orlistat treatment were associated with limited cases of severe hepatic adversative effects such as cholelithiasis, cholostatic</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of the mean area percentage of Hep-Par1 between experimental groups</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Groups</th><th align="center" valign="middle"  colspan="4"  >Mean &#177; SD (%)</th></tr></thead><tr><td align="center" valign="middle" >Control group</td><td align="center" valign="middle" >β-Carotene</td><td align="center" valign="middle" >Orlistat group</td><td align="center" valign="middle" >β-Carotene &amp; Orlistat</td></tr><tr><td align="center" valign="middle" >Area %</td><td align="center" valign="middle" >77.65 &#177; 3.66</td><td align="center" valign="middle" >77.47 &#177; 3.75</td><td align="center" valign="middle" >58.85 &#177; 7.95*</td><td align="center" valign="middle" >70.75 &#177; 5.23**</td></tr></tbody></table></table-wrap><p>The values are expressed as mean &#177; SD. Non-significant between group I &amp; group II. *Test of significance between control rats and orlistat treated rats at p &lt; 0.001. **Test of significance between orlistat treated rats and β-Carotene &amp; Orlistat treated rats at p &lt; 0.001.</p><p>hepatitis and subacute liver failures [<xref ref-type="bibr" rid="scirp.83958-ref14">14</xref>]. Importantly, FDA received thirty two cases reports of serious liver injury in patients using orlistat, including 6 cases of liver failure from 1999 to 2008 [<xref ref-type="bibr" rid="scirp.83958-ref32">32</xref>]. In contrast, Orlistat 120 mg in combination with diet has been shown to reduce liver fat in patients with type 2 diabetes [<xref ref-type="bibr" rid="scirp.83958-ref8">8</xref>] and non-alcoholic steatohepatitis, and reduce inflammation and fibrosis in non-alcoholic steatohepatitis [<xref ref-type="bibr" rid="scirp.83958-ref9">9</xref>]. Clinically, orlistat was linked with pancreatitis in some cases. Orlistat was connected with acute pancreatitis with no sign of biliary disease in several cases [<xref ref-type="bibr" rid="scirp.83958-ref14">14</xref>]. Crucially, the most obvious associations between orlistat and pancreatitis appeared to be due to cholelithiasis and increased alcohol consumption by obese participant.</p><p>In the present study, bile ductules proliferation observed in the orlistat treated rats. Some researchers recommended that the ductular reactions that happen in response to various liver damages [<xref ref-type="bibr" rid="scirp.83958-ref33">33</xref>].</p><p>In the present research, improvement of orlistat was well demonstrated in rats treated with β-carotene. The liver tissues had preserved in the orlistat and β-carotene group. The hepatocytes were relatively normal, with vesicular nuclei. The portal areas were not apparently infiltrated with inflammatory cells. In agreement with present assumption, a previous study reported that two thirds of a supplemental dose of β-carotene will be absorbed during orlistat treatment; this may be sufficient to achieve physiologic levels of β-carotene. It has been shown to prevent the oxidant-mediated activation of inflammatory signaling. β-carotene removed superoxide radicals and it played an important role in defending cells from these radicals [<xref ref-type="bibr" rid="scirp.83958-ref34">34</xref>].</p><p>In the current work, PAS-stained sections of the control group showed normal content of glycogen granules evidenced by a strong PAS reaction. In contrast, the orlistat treated group showed focal weak PAS positive reaction indicating depletion of glycogen. Sakr and his colleague suggested that the reduction in carbohydrate contents could be due to increased stress on the liver, leading to the consumption of high energy in an attempt to diminish or balance the pressure exerted on it [<xref ref-type="bibr" rid="scirp.83958-ref35">35</xref>]. Other researchers suggested that damages carbohydrate metabolism might be due to the inhibition of the intestinal absorption of nutrients and inhibition of hepatic gluconeogenesis [<xref ref-type="bibr" rid="scirp.83958-ref36">36</xref>].</p><p>In the present study, all the studied groups of Hep-Par1 sections showed a negative immunoreactive zone around the central veins which were narrow in the control and and β-carotene group. In contrast, very wide negative immunoreactive area in the orlistat group. Previous investigators recommended that the comparative cellular hypoxia that disturbed mitochondrial metabolic pathways in the level of hepatocytes nearby to the central vein might clarify the negative immunoreactive of this area [<xref ref-type="bibr" rid="scirp.83958-ref37">37</xref>].</p><p>In this study, the electron microscopic investigations of orlistat group displayed obvious ultrastructure changes confirmed the light microscopic results. Some cells showed the nuclei often appeared with irregular shapes and chromatin condensation. Other damaged cells seemed with pyknotic nuclei and vacuolated cytoplasm. Moreover, the most obvious degenerative changes appeared in the form of dilated rough endoplasmic reticulum. Definitely, the endoplasmic reticulum was especially liable to the free radical attack, because it is considered as a site of radical production. In addition, its membrane is rich in polyunsaturated fatty acids which are vulnerable to free radical attack. Therefore, the degenerative changes in the endoplasmic reticulum might be due to increased oxidative stress [<xref ref-type="bibr" rid="scirp.83958-ref38">38</xref>].</p><p>In the present work, the ultrastructure study of orlistat treated rat showed the electron density of the mitochondrial matrix and swollen mitochondria. The ultrastructure of the mitochondria and its function were definitely impaired. In accordance with present study, other researchers documented that the electron density of the mitochondrial matrix has been attributed to oxidative stress. Then the active substance initially in the mitochondria correlated to apoptosis, including cytochrome c was released into the cytoplasm [<xref ref-type="bibr" rid="scirp.83958-ref39">39</xref>]. The swollen mitochondria are the major morphological changes in the mitochondrial injury [<xref ref-type="bibr" rid="scirp.83958-ref40">40</xref>]. In addition, Johar &amp; coworker suggested that apoptosis could be followed by mitochondrial swelling, endoplasmic reticulum dilatation and lysosomal rupture before reduction and termination of nuclei [<xref ref-type="bibr" rid="scirp.83958-ref41">41</xref>]. Other study, in diabetic rat stated that, swelling mitochondria by about 28% as compensation of reduced mitochondrial ATP production and membranes injured by hydroxyl radicals [<xref ref-type="bibr" rid="scirp.83958-ref42">42</xref>].</p><p>The present work proved that co-administration of β-carotene was effective in decreasing the harmful effect of orlistat in the liver of male adult albino rats. This was detected by both light and electron microscopic studies. This perfection might be secondary to the antioxidant ability of β-carotene, which attacks reactive oxygen species (ROS) and thus neutralizes their detrimental effects on the tissues. Fukuzawa and coworker reported that β-Carotene acts as an antioxidant by scavenging free radicals and quenching singlet oxygen [<xref ref-type="bibr" rid="scirp.83958-ref18">18</xref>]. It was found that β-Carotene could have a radical scavenging effect prevented ethanol-induced liver damage and it increased the reduced glutathione (GSH) concentration in rats [<xref ref-type="bibr" rid="scirp.83958-ref43">43</xref>]. Recent report suggested that β-carotene had distinguished ameliorative effect against arsenic prompted toxicity in albino mice intervened by its antioxidant and antigenotoxic properties [<xref ref-type="bibr" rid="scirp.83958-ref44">44</xref>]. The effective role of β-carotene supplementation was studied previously and it was reported that the ethanol-induced hepatic depletion of vitamin A can be corrected by β-carotene supplementation per day [<xref ref-type="bibr" rid="scirp.83958-ref45">45</xref>].</p></sec><sec id="s5"><title>5. Conclusion</title><p>Clinicians should be aware and carefully monitor their patients on orlistat medication for signs of hepatic dysfunction. The administration of β-carotene might protect against liver damage produced by orlistat.</p></sec><sec id="s6"><title>Cite this paper</title><p>Youssef, S. (2018) Light and Electron Microscopic Study of the Effect of Orlistat on the Liver of Adult Male Albino Rats and the Possible Protective Role of β-Carotene. Forensic Medicine and Anatomy Research, 6, 20-36. https://doi.org/10.4236/fmar.2018.62003</p></sec></body><back><ref-list><title>References</title><ref id="scirp.83958-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kang, J.G. and Park, C.Y. (2012) Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes &amp; Metabolism Journal, 36, 13-25.  
https://doi.org/10.4093/dmj.2012.36.1.13</mixed-citation></ref><ref id="scirp.83958-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Heal, D.J., Gosden, J. and Smith, S.L. (2012) What Is the Prognosis for New Centrally-Acting Anti-Obesity Drugs? Neuropharmacology, 63,132-146.  
https://doi.org/10.1016/j.neuropharm.2012.01.017</mixed-citation></ref><ref id="scirp.83958-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhi, J., Melia, A. T., Funk, C., Viger-Chougnet, A., Hopfgartner, G. and Lausecker, B. (1996) Metabolic Profiles of Minimally Absorbed Orlistat in Obese/Overweight Volunteers. The Journal of Clinical Pharmacology, 36, 1006-1011.  
https://doi.org/10.1177/009127009603601104</mixed-citation></ref><ref id="scirp.83958-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Sjostrom, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A. and Koppeschaar, H.P. (1998) Randomised Placebo-Controlled Trial of Orlistat for Weight Loss and Prevention of Weight Regain in Obese Patients. European Multicentre Orlistat Study Group. The Lancet, 352, 167-172.  
https://doi.org/10.1016/S0140-6736(97)11509-4</mixed-citation></ref><ref id="scirp.83958-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hogan, S., Fleury, A., Hadvary, P., Lengsfeld, H., Meier, M.K. and Triscari, J. (1987) Studies on the Antiobesity Activity of Tetrahydrolipstatin, A Potent and Selective Inhibitor of Pancreatic Lipase. International Journal of Obesity (London), 11, 35-42.</mixed-citation></ref><ref id="scirp.83958-ref6"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guerciolini</surname><given-names> R. </given-names></name>,<etal>et al</etal>. (<year>1997</year>)<article-title>Mode of Action of Orlistat</article-title><source> International Journal of Obesity and Related Metabolic Disorders</source><volume> 21</volume>,<fpage> S12</fpage>-<lpage>S23</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.83958-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Torgerson, J.S., Hauptman, J., Boldrin, M.N. and Sjostrom, L. (2004) XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. Diabetes Care, 27, 155-161. https://doi.org/10.2337/diacare.27.1.155</mixed-citation></ref><ref id="scirp.83958-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kelley, D.E., Kuller, L.H., McKolanis, T.M., Harper, P., Mancino, J. and Kalhan, S. (2004) Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes. Diabetes Care, 27, 33-40.  
https://doi.org/10.2337/diacare.27.1.33</mixed-citation></ref><ref id="scirp.83958-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hussein, O., Grosovski, M., Schlesinger, S., Szvalb, S. and Assy, N. (2007) Orlistat Reverses Fatty Infiltration and Improves Hepatic Fibrosis in Obese Patients with Nonalcoholic Steatohepatitis (NASH). Digestive Diseases and Sciences, 52, 2512-2519.  
https://doi.org/10.1007/s10620-006-9631-1</mixed-citation></ref><ref id="scirp.83958-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Siebenhofer, A., Horvath, K., Jeitler, K., Berghold, A., Stich, A.K. and Matyas, E. (2009) Long-Term Effects of Weight-Reducing Drugs in Hypertensive Patients. Cochrane Database of Systematic Reviews, 3, CD007654.</mixed-citation></ref><ref id="scirp.83958-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Muls, E., Kolanowski, J., Scheen, A. and L Van Gaal ObelHyx Study Group (2001) The Effects of Orlistat on Weight and on Serum Lipids in Obese Patients with Hypercholesterolemia: A Randomized, Double Blind, Placebo-Controlled Multicentre Study. International Journal of Obesity, 25, 1713-1721.  
https://doi.org/10.1038/sj.ijo.0801814</mixed-citation></ref><ref id="scirp.83958-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Song, J., Ruan, X., Gu, M., Wang, L., Wang, H. and Mueck, A.O. (2017) Effect of Orlistat or Metformin in Overweight and Obese Polycystic Ovary Syndrome Patients with Insulin Resistance. Gynecological Endocrinology, 24, 1-5.</mixed-citation></ref><ref id="scirp.83958-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Caner, M., Dogruman, H., Taskin, E., Kandil, A. and Demirci, C. (2005) Effects of Orlistat and Its Relationship with Nitric Oxide in the Small Intestinal Mucosa. Chinese Journal of Physiology, 48, 217-222.</mixed-citation></ref><ref id="scirp.83958-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Filippatos, T.D., Derdemezis, C.S, Gazi, I.F., Nakou, E.S., Mikhailidis, D.P. and Elisaf, M.S. (2008) Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review. Drug Safety, 31, 53-65.  
https://doi.org/10.2165/00002018-200831010-00005</mixed-citation></ref><ref id="scirp.83958-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kose, M., Emet, S., Akp&amp;inodot;nara, T.S. and Ilhanc, M. (2015) An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis. Case Reports in Gastroenterology, 9, 152-155. https://doi.org/10.1159/000430433</mixed-citation></ref><ref id="scirp.83958-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Padwal, R.S. and Majumdar, S.R. (2007) Drug Treatments for Obesity: Orlistat, Sibutramine, and Rimonabant. The Lancet, 369, 71-77.  
https://doi.org/10.1016/S0140-6736(07)60033-6</mixed-citation></ref><ref id="scirp.83958-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Saini, R.K., Nile, S.H. and Park, S.W. (2015) Carotenoids from Fruits and Vegetables: Chemistry, Analysis, Occurrence, Bioavailability and Biological Activities. Food Research International, 76, 735-750.  
https://doi.org/10.1016/j.foodres.2015.07.047</mixed-citation></ref><ref id="scirp.83958-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Fukuzawa, K., Inokami, Y. and Tokumura, A. (1998) Rate Constants for Quenching Singlet Oxygen and Activities for Inhibiting Lipid Peroxidation of Carotenoids and Alpha-Tocopherol in Liposomes. Lipids, 33, 751-756.  
https://doi.org/10.1007/s11745-998-0266-y</mixed-citation></ref><ref id="scirp.83958-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Fraser, P.D. and Bramley, P.M. (2004) The Biosynthesis and Nutritional Uses of Carotenoids. Progress in Lipid Research, 43, 228-265.  
https://doi.org/10.1016/j.plipres.2003.10.002</mixed-citation></ref><ref id="scirp.83958-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Van Poppel, G. (1993) Carotenoids and Cancer: An Update with Emphasis on Human Intervention Studies. European Journal of Cancer, 29A, 1335-1344.  
https://doi.org/10.1016/0959-8049(93)90087-V</mixed-citation></ref><ref id="scirp.83958-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Handelman, G.J., van Kuijk, F.J.G.M., Chatterjee, A. and Krinsky, N.I. (1991) Characterization of Products Formed during the Autoxidation of β-Carotene. Free Radical Biology &amp; Medicine, 10, 427-437.  
https://doi.org/10.1016/0891-5849(91)90051-4</mixed-citation></ref><ref id="scirp.83958-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chu, P.G., Ishizawa, S., Wu, E. and Weiss, L.M. (2002) Hepatocyte Antigen as a Marker of Hepatocellular Carcinoma: An Immunohistochemical Comparison to Carcinoembryonic Antigen, CD10, and Alpha-Fetoprotein. The American Journal of Surgical Pathology, 26, 978-988.  
https://doi.org/10.1097/00000478-200208000-00002</mixed-citation></ref><ref id="scirp.83958-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Peng, H.C., Chen, Y.L., Yang, S.Y., et al. (2013) The Antiapoptotic Effects of Different Doses of β-Carotene in Chronic Ethanol-Fed Rats. Hepatobiliary Surgery and Nutrition, 2, 132-141.</mixed-citation></ref><ref id="scirp.83958-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Cruz Hernandez, C., Oliveira, M., Pescia, G., Moulin, J., Masserey Elmelegy, I., Dionisi, F. and Destaillats, F. (2010) Lipase Inhibitor Orlistat Decreases Incorporation of Eicosapentaenoic and Docosahexaenoic Acids in Rat Tissues. Nutrition Research, 30, 134-140. https://doi.org/10.1016/j.nutres.2009.12.001</mixed-citation></ref><ref id="scirp.83958-ref25"><label>25</label><mixed-citation publication-type="book" xlink:type="simple">Paget, G.E. and Branes, G.M. (1964) Toxicity Tests. In: Laurence, D.R. and Bacharach, A.L., Eds., Evaluation of Drug Activities: Pharmacometrics, Vol. 1, 2nd Edition, Academic Press, London. https://doi.org/10.1016/B978-1-4832-2845-7.50012-8</mixed-citation></ref><ref id="scirp.83958-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Bancroft, J.D. and Gamble, M. (2013) Theory and Practice of Histological Techniques. 7th Edition, Churchill Livingstone of Elsevier, Philadelphia, 172-186.</mixed-citation></ref><ref id="scirp.83958-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Bancroft, J.D. and Stevens, A. (1996) Theory and Practice of Histotechnological Techniques. 4th Edition, Churchill Livingstone, New York.</mixed-citation></ref><ref id="scirp.83958-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Abdelrahman, A.E., Abdel-Aziz, H.R. and Hegazy, A.A. (2015) Immunohistochemical Distinction of Hepatocellular Carcinoma Using Arginase-1, Hepatocyte Paraffin Antigen-1 and Glypican-3. Journal of Tumor, 4, 359-366.  
https://doi.org/10.17554/j.issn.1819-6187.2016.04.75</mixed-citation></ref><ref id="scirp.83958-ref29"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>AL-Rawi</surname><given-names> M.M. </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>Effect of Trifolium sp. Flowers Extracts on the Status of Liver Histology of STZ-Induced Diabetic Rats</article-title><source> Saudi Journal of Biological Sciences</source><volume> 14</volume>,<fpage> 21</fpage>-<lpage>28</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.83958-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Atiq, M., Davis, J.C., Lamps, L.W., Beland, S.S. and Rose, J.E. (2009) Amiodarone Induced Liver Cirrhosis. Report of Two Cases. Journal of Gastrointestinal and Liver Diseases, 18, 233-235.</mixed-citation></ref><ref id="scirp.83958-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Bu, D.X., Erl, W., De Martin, R., Hansson, G.K. and Yan, Z.-Q. (2005) IKK β-Dependent NF-κB Pathway Controls Vascular Inflammation and Intimal Hyperplasia. The FASEB Journal, 19, 1293-1295. https://doi.org/10.1096/fj.04-2645fje</mixed-citation></ref><ref id="scirp.83958-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">U.S. Food and Drug Administration (2010) FDA Drug Safety Communication. Completed Safety Review of Xenical/Alli (orlistat) and Severe Liver Injury. 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand 
Providers/ucm213038.htm</mixed-citation></ref><ref id="scirp.83958-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">LeSage, G., Glaser, S. and Alpini, G. (2001) Regulation of Cholangiocyte Proliferation. Liver, 21, 73-80. https://doi.org/10.1034/j.1600-0676.2001.021002073.x</mixed-citation></ref><ref id="scirp.83958-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Jang, S.H., Lim, J.W. and Kim, H.B. (2009) Carotene Inhibits Helicobacter Pylori-Induced Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Human Gastric Epithelial AGS cells. Journal of Physiology and Pharmacology, 60, 131-137.</mixed-citation></ref><ref id="scirp.83958-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Sakr, S.A., Abdel Samei, H.A. and Soliman, M.E. (2004) Exploring Hepatotoxicity of Benomyl. Histological and Histochemical Study on Albino Rats. Journal of Medical Sciences, 4, 77-83. https://doi.org/10.3923/jms.2004.77.83</mixed-citation></ref><ref id="scirp.83958-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Gopumadhavan, S., Mohammed, R., Azeemuddin, M. and Mitra, S.K. (2008) Ameliorative Effect of Partysmart in Rat Model of Alcoholic Liver Disease. Indian Journal of Experimental Biology, 46, 132-137.</mixed-citation></ref><ref id="scirp.83958-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Shehata, A.S., Mohamed, Z.A., Abd El-Haleem, M.R. and Samak, M.A. (2013) Effects of Exposure to Plasticizers Di-(2-Ethylhexyl) Phthalate and Trioctyltrimellitate on the Histological Structure of Adult Male Albino Rats’ Liver. Journal of Clinical Toxicology, 3, 4.</mixed-citation></ref><ref id="scirp.83958-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Pradeep, K., Raj Mohan, C.V., Gobianand, K. and Karthikeyan, S. (2010) Protective Effect of Cassia fistula Linn. on Diethylnitrosamine Induced Hepatocellular Damage and Oxidative Stress in Ethanol Pretreated Rats. Biological Research, 43, 113-125.  
https://doi.org/10.4067/S0716-97602010000100013</mixed-citation></ref><ref id="scirp.83958-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Aliev, G., Palacios, H.H., Gasimov, E., Obrenovich, M.E., Morales, L., Leszek, J., et al. (2010) Oxidative Stress Induced Mitochondrial Failure and Vascular Hypoperfusion as a Key Initiator for the Development of Alzheimer Disease. Pharmaceuticals, 3, 158-187. https://doi.org/10.3390/ph3010158</mixed-citation></ref><ref id="scirp.83958-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Lu, X., Hamilton, J.A., Shen, J., Pang, T., Jones, D.L. and Potter, R.F. (2006) Role of Tumor Necrosis Factor-Alpha in Myocardial Dysfunction and Apoptosis during Hind Limb Ischemia and Reperfusion. Critical Care Medicine, 34, 484-491.  
https://doi.org/10.1097/01.CCM.0000199079.64231.C1</mixed-citation></ref><ref id="scirp.83958-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Johar, D., Roth, J.C., Bay, G.H., Walker, J.N., Kroczak, T.J. and Los, M. (2004) Inflammatory Response, Reactive Oxygen Species, Programmed (Necrotic-Like and Apoptotic) Cell Death and Cancer. Roczniki Akademii Medycznej W Bialymstoku, 49, 31-39.</mixed-citation></ref><ref id="scirp.83958-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Ohkuwa, T., Sato, K. and Naoi, M. (1995) Hydrozyl Radical Formation in Diabetic Rat Induced by Streptozotocin. Life Sciences, 56, 1789-1798.  
https://doi.org/10.1016/0024-3205(95)00150-5</mixed-citation></ref><ref id="scirp.83958-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Lin, W.T., Huang, C.C., Lin, T.J., et al. (2009) Effects of Beta Carotene on Antioxidant Status in Rats with Chronic Alcohol Consumption. Cell Biochemistry and Function, 27, 344-350. https://doi.org/10.1002/cbf.1579</mixed-citation></ref><ref id="scirp.83958-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Das, R., Das, A., Roy, A., Kumari, U., Bhattacharya, S. and Haldar, P.K. (2015) β-Carotene Ameliorates Arsenic-Induced Toxicity in Albino Mice. Biological Trace Element Research, 164, 226-233. https://doi.org/10.1007/s12011-014-0212-4</mixed-citation></ref><ref id="scirp.83958-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, S., Leo, M.A. and Lieber, C.S. (1994) Interactions between Alcohol and Beta-Carotene in Patients with Alcoholic Liver Disease. The American Journal of Clinical Nutrition, 60, 430-436. https://doi.org/10.1093/ajcn/60.3.430</mixed-citation></ref></ref-list></back></article>